Abstract: Slide Presentations |

Omalizumab, an Anti-IgE Antibody, Provides Parallel Improvements in Symptoms of Allergic Asthma and Perennial Allergic Rhinitis in Patients With Both Diseases: The SOLAR Study FREE TO VIEW

Louis-Philippe Boulet, MD; Giorgio W. Canonica, MD; Ronald Dahl, MD; Simon Hedgecock, BSc; Martin Blogg, BSc (Hons); Karen Surrey, MSc; Howard Fox, MD
Author and Funding Information

Institut de cardiologie et de pneumologie de l’Université Laval, Hopital Laval, Quebec City, PQ, Canada


Chest. 2003;124(4_MeetingAbstracts):105S. doi:10.1378/chest.124.4_MeetingAbstracts.105S-a
Text Size: A A A
Published online


PURPOSE:  Patients with allergic asthma (AA) frequently experience concomitant perennial allergic rhinitis (PAR). Omalizumab, a humanized monoclonal anti-IgE antibody, improves symptoms and disease control in patients with AA or PAR. In this study, we evaluated the efficacy of omalizumab in patients with concomitant AA and PAR.

METHODS:  This was a 28-week, randomized, double-blind, placebo-controlled multicenter trial of 405 patients with moderate–severe AA and concomitant moderate–severe PAR. Patients (12–74 years) were randomized to receive either omalizumab (n=209) [at least 0.016mg/kg/IgE(IU/mL) per 4 weeks] or placebo (n=196) for 28 weeks, in addition to current therapies (inhaled budesonide Turbuhaler [≥400 μg/day] plus optional long-acting β2-agonist and/or nasal steroids). Efficacy parameters included AA and PAR clinical symptom scores (40 and 44 point scale for asthma and rhinitis, respectively), investigator global evaluations of treatment effectiveness, asthma exacerbations, and asthma-and-rhinitis-related quality of life (QoL).

RESULTS:  Omalizumab resulted in significant reductions from baseline in both asthma and rhinitis clinical symptom scores at study end. Asthma symptom scores decreased by an (adjusted) mean of 8.4 points (baseline 16.4) with omalizumab compared with a decrease of 6.6 (baseline 16.2) for placebo (p<0.05). Investigators rated asthma symptom control as excellent/good in 59.3% omalizumab-treated patients compared with 41.3% patients in the placebo group (p<0.001). Rhinitis symptom scores decreased by an (adjusted) mean of 9.3 points (baseline 21.9) with omalizumab compared with 5.8 (baseline 21.8) for placebo (p<0.001). More omalizumab patients had their rhinitis symptom control rated as excellent/good by investigators than placebo (54.5% vs 26.5%, p<0.001). Omalizumab decreased the asthma exacerbation rate by 39% compared with placebo (p<0.05) and improved combined asthma-and-rhinitis-related QoL scores at study end compared with placebo (p<0.001).CONCLUSIONS: Omalizumab provides parallel improvements in asthma and rhinitis symptoms in patients with both moderate–severe allergic asthma and perennial allergic rhinitis.

CLINICAL IMPLICATIONS:  Anti-IgE therapy with omalizumab is an effective add-on therapy in patients with co-morbid AA and PAR.

DISCLOSURE:  L. Boulet, Research funded by Novartis Pharma AG and Genentech, Industry.

Tuesday, October 28, 2003

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep 2004;4(3):237-44.
Current status of therapy with omalizumab in children. Curr Opin Allergy Clin Immunol 2014;14(2):149-54.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543